#AMRN Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VAS…
https://www.stocktitan.net/news/AMRN/amarin-provides-update-on-university-of-leeds-sponsored-phase-3-epa-dls9jlkhdt8y.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/AMRN/amarin-provides-update-on-university-of-leeds-sponsored-phase-3-epa-dls9jlkhdt8y.html?utm_source=stocktitan-bluesky&utm_medium=social
Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
October 25, 2026 at 12:11 PM
#AMRN Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VAS…
https://www.stocktitan.net/news/AMRN/amarin-provides-update-on-university-of-leeds-sponsored-phase-3-epa-dls9jlkhdt8y.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/AMRN/amarin-provides-update-on-university-of-leeds-sponsored-phase-3-epa-dls9jlkhdt8y.html?utm_source=stocktitan-bluesky&utm_medium=social
Latest company news, August 31: Amarin presented new REDUCE-IT and EPA analyses at ESC Congress 2026, including lipoprotein(a) data on 5,036 participants.
Amarin (#$AMRN): Can VASCEPA and Its Partners Build Lasting Cash Flow?
www.merlintrader.com/amarin-amrn-...
Amarin (#$AMRN): Can VASCEPA and Its Partners Build Lasting Cash Flow?
www.merlintrader.com/amarin-amrn-...
Amarin ($AMRN): VASCEPA, Partners And Cash Flow
Amarin ($AMRN): VASCEPA economics, partner growth, positive operating cash flow, REDUCE-IT evidence and the conditions behind the 2026 outlook.
www.merlintrader.com
October 6, 2026 at 10:18 PM
Latest company news, August 31: Amarin presented new REDUCE-IT and EPA analyses at ESC Congress 2026, including lipoprotein(a) data on 5,036 participants.
Amarin (#$AMRN): Can VASCEPA and Its Partners Build Lasting Cash Flow?
www.merlintrader.com/amarin-amrn-...
Amarin (#$AMRN): Can VASCEPA and Its Partners Build Lasting Cash Flow?
www.merlintrader.com/amarin-amrn-...
Reviewing the serving instructions and physical format before purchasing can help avoid an inconvenient daily routine. Click here know more about #vascepavslovaza omegadirectshop.com/blogs/news/p...
Prescription vs OTC: Vascepa, Lovaza vs Fish Oil
Vascepa and Lovaza are prescription omega-3 drugs for very high triglycerides. See how they differ from OTC fish oil and where a quality supplement fits.
omegadirectshop.com
September 30, 2026 at 11:27 AM
Reviewing the serving instructions and physical format before purchasing can help avoid an inconvenient daily routine. Click here know more about #vascepavslovaza omegadirectshop.com/blogs/news/p...
Potential Use of Icosapent Ethyl in the Management of Acute Pancreatitis
Abosheaishaa et al. — ASIDE Gastroenterology
https://asidejournals.com/index.php/Gastroenterology/article/view/6
Abosheaishaa et al. — ASIDE Gastroenterology
https://asidejournals.com/index.php/Gastroenterology/article/view/6
Potential Use of Icosapent Ethyl in the Management of Acute Pancreatitis
Dear Editor, We are writing to highlight the potential use of Icosapent Ethyl (Vascepa) as a management option for acute pancreatitis. To the best of my knowledge, a limited number of studies have…
asidejournals.com
August 29, 2026 at 2:40 PM
Potential Use of Icosapent Ethyl in the Management of Acute Pancreatitis
Abosheaishaa et al. — ASIDE Gastroenterology
https://asidejournals.com/index.php/Gastroenterology/article/view/6
Abosheaishaa et al. — ASIDE Gastroenterology
https://asidejournals.com/index.php/Gastroenterology/article/view/6
BREAKING: A 9-0 Supreme Court *tightens* requirements for lawsuits alleging a “skinny label” generic drug manufacturer induced infringement of the name-brand product, ending a dispute over the alleged infringement of Amarin Pharma’s Vascepa drug. #SCOTUS www.supremecourt.gov/opinions/25p...
June 4, 2026 at 2:15 PM
BREAKING: A 9-0 Supreme Court *tightens* requirements for lawsuits alleging a “skinny label” generic drug manufacturer induced infringement of the name-brand product, ending a dispute over the alleged infringement of Amarin Pharma’s Vascepa drug. #SCOTUS www.supremecourt.gov/opinions/25p...
really grateful for @mcuban.bsky.social's @costplusdrugs.com
look at cost difference from even previously cheapest sources
for this new medication I'm desperately trying for #LongCovid
Would not even be able to afford it otherwise
Exhausted all savings after so many years sick
Expensive to be poor
look at cost difference from even previously cheapest sources
for this new medication I'm desperately trying for #LongCovid
Would not even be able to afford it otherwise
Exhausted all savings after so many years sick
Expensive to be poor
September 24, 2025 at 5:24 PM
really grateful for @mcuban.bsky.social's @costplusdrugs.com
look at cost difference from even previously cheapest sources
for this new medication I'm desperately trying for #LongCovid
Would not even be able to afford it otherwise
Exhausted all savings after so many years sick
Expensive to be poor
look at cost difference from even previously cheapest sources
for this new medication I'm desperately trying for #LongCovid
Would not even be able to afford it otherwise
Exhausted all savings after so many years sick
Expensive to be poor
learned not to get hopeful anymore
about supplement treatments for #LongCovid
filled garbage-bag full of empty bottles
each year 2020, 2021, 2022, 2023, 2024, 2025
of various things desperately tried
horrible cycle, hope->nada->depression
but more I read about mega-dose EPA/Vascepa
hopeful again?
about supplement treatments for #LongCovid
filled garbage-bag full of empty bottles
each year 2020, 2021, 2022, 2023, 2024, 2025
of various things desperately tried
horrible cycle, hope->nada->depression
but more I read about mega-dose EPA/Vascepa
hopeful again?
EPA Deficiency Syndrome.docx (2).pdf
Dietary changes in the past 50 years has caused a deficiency in EPA in most people which has lead to an increase in cardiovascular disease, obesity, diabetes & much more. WHY: This project has been th...
drive.google.com
September 19, 2025 at 5:31 PM
learned not to get hopeful anymore
about supplement treatments for #LongCovid
filled garbage-bag full of empty bottles
each year 2020, 2021, 2022, 2023, 2024, 2025
of various things desperately tried
horrible cycle, hope->nada->depression
but more I read about mega-dose EPA/Vascepa
hopeful again?
about supplement treatments for #LongCovid
filled garbage-bag full of empty bottles
each year 2020, 2021, 2022, 2023, 2024, 2025
of various things desperately tried
horrible cycle, hope->nada->depression
but more I read about mega-dose EPA/Vascepa
hopeful again?
Saved me $500 per quarter on Vascepa…
April 23, 2026 at 7:48 PM
Saved me $500 per quarter on Vascepa…
Thanks to @mcuban.bsky.social and CostPlus Drugs, my 91yo mom saved a bunch of money on her meds!
Vascepa $427 —> $74
Solifenacin $47 —> $10
Esomeprazole $65 —> $14
Vascepa $427 —> $74
Solifenacin $47 —> $10
Esomeprazole $65 —> $14
January 21, 2025 at 8:38 PM
Thanks to @mcuban.bsky.social and CostPlus Drugs, my 91yo mom saved a bunch of money on her meds!
Vascepa $427 —> $74
Solifenacin $47 —> $10
Esomeprazole $65 —> $14
Vascepa $427 —> $74
Solifenacin $47 —> $10
Esomeprazole $65 —> $14
2026-06-04 22:06:33 - Xikma Pharmaceuticals' stock price hit an intraday high after the U.S. Supreme Court ruled in favor of the company in the VASCEPA patent dispute. The stock price rose 3.3%.
June 4, 2026 at 2:10 PM
2026-06-04 22:06:33 - Xikma Pharmaceuticals' stock price hit an intraday high after the U.S. Supreme Court ruled in favor of the company in the VASCEPA patent dispute. The stock price rose 3.3%.
Really feels like game over for apoc3i. Look at this side by side with evaporate and vascepa. They got a slam dunk drop in plaque volume with just 80 subjects. Interestingly evaporate came out after reduce -it but this seems like an awesome gate keeper phase2 for all pipeline drugs
EFFECT OF ICOSAPENT ETHYL ON PERCENT ATHEROMA VOLUME IN PATIENTS WITH ELEVATED TRIGLYCERIDES ON STATIN THERAPY - INSIGHTS FROM THE EVAPORATE TRIAL:
www.jacc.org
March 31, 2026 at 5:08 PM
Really feels like game over for apoc3i. Look at this side by side with evaporate and vascepa. They got a slam dunk drop in plaque volume with just 80 subjects. Interestingly evaporate came out after reduce -it but this seems like an awesome gate keeper phase2 for all pipeline drugs
If you are in West Palm Beach #Florida 12/10/2024 - come join me for a medical round table on Vascepa.
Register here:
na.eventscloud.com/ereg/index.p...
#CardioSky #MedSky #PASky #NPSky #PhysicianAssociate #PAtientsHealthFirst #IPE #OM3 #EPA
Register here:
na.eventscloud.com/ereg/index.p...
#CardioSky #MedSky #PASky #NPSky #PhysicianAssociate #PAtientsHealthFirst #IPE #OM3 #EPA
December 9, 2024 at 3:40 AM
If you are in West Palm Beach #Florida 12/10/2024 - come join me for a medical round table on Vascepa.
Register here:
na.eventscloud.com/ereg/index.p...
#CardioSky #MedSky #PASky #NPSky #PhysicianAssociate #PAtientsHealthFirst #IPE #OM3 #EPA
Register here:
na.eventscloud.com/ereg/index.p...
#CardioSky #MedSky #PASky #NPSky #PhysicianAssociate #PAtientsHealthFirst #IPE #OM3 #EPA
Hikma Pharms. USA Inc. v. Amarin Pharma, Inc.
Hikma Pharms. USA Inc. v. Amarin Pharma, Inc.
Amarin markets Vascepa, a branded icosapent ethyl product. In 2012, the FDA approved Vascepa for treatment of severe hypertriglyceridemia (“the...
www.jdsupra.com
July 14, 2026 at 6:55 PM
Hikma Pharms. USA Inc. v. Amarin Pharma, Inc.
U.S. Supreme Court Addresses Liability for Patent Infringement by Generic Pharmaceuticals
U.S. Supreme Court Addresses Liability for Patent Infringement by Generic Pharmaceuticals
In a unanimous opinion by Justice Ketanji Brown Jackson, the U.S. Supreme Court held that Amarin, the developer of Vascepa® (reference listed...
www.jdsupra.com
June 9, 2026 at 11:13 AM
U.S. Supreme Court Addresses Liability for Patent Infringement by Generic Pharmaceuticals